Market revenue in 2022 | USD 3,107.4 million |
Market revenue in 2030 | USD 21,132.4 million |
Growth rate | 27.1% (CAGR from 2022 to 2030) |
Largest segment | Cell therapy |
Fastest growing segment | Gene Therapy |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy |
Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 57.15% in 2022. Horizon Databook has segmented the U.S. cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. held the highest revenue share in North America cell and gene therapy manufacturing market owing to presence of key market players, including CDMOs offering GMP manufacturing services, and adoption of highly innovative manufacturing technologies for production.
These major players are undertaking various strategic initiatives to boost their market presence, in turn, leading to market growth in the country. For instance, in February 2020, Audients Therapeutics invested USD 109 million in new gene therapy manufacturing facility in North Carolina.
With this, the company aimed at increasing its in-house production capacity. Moreover, earlier in January 2020, Hitachi Chemical Advanced Therapeutics Solutions opened a new cell and gene therapy manufacturing facility in New Jersey.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. cell and gene therapy manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into U.S. cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account